Furanone quorum-sensing inhibitors with potential as novel therapeutics against Pseudomonas aeruginosa

Research output: Contribution to journalReview articlepeer-review

40 Citations (Scopus)
275 Downloads (Pure)


Micro-organisms use quorum sensing (QS), a cell density-dependent process, to communicate. This QS mode of interchange leads to the production of a variety of virulence factors, co-ordination of complex bacterial behaviours, such as swarming motility, degradation of host tissue and biofilm formation. QS is implicated in numerous human infections and consequently researchers have sought ways of effectively inhibiting the process in pathogenic bacteria. Two decades ago, furanones were the first class of chemical compounds identified as Pseudomonas aeruginosa QS inhibitors (QSIs). P. aeruginosa is a ubiquitous organism, capable of causing a wide range of infections in humans, including eye and ear infections, wound infections and potentially fatal bacteraemia and thus novel treatments against this organism are greatly needed. This review provides a brief background on QS and the use of furanones as QSIs. Based on the effectiveness of action, both in vivo and in vitro, we will explore the use of furanones as potential antimicrobial therapeutics and conclude with open questions.
Original languageEnglish
Pages (from-to)195-206
Number of pages12
JournalJournal of Medical Microbiology
Issue number2
Early online date23 Jan 2020
Publication statusPublished online - 23 Jan 2020

Bibliographical note

Funding Information:
C.R.P. was supported by a Department for the Economy (Northern Ireland) Ph.D. studentship (2017-2020). P.A.M. and N.G.T. were supported by strategic funding from the Biomedical Sciences Research Institute, University of Ulster, Coleraine.

Publisher Copyright:
© 2020 The Authors.

Copyright 2020 Elsevier B.V., All rights reserved.


  • Pseudomonas and furanone
  • quorum sensing
  • biofilm
  • therapeutic


Dive into the research topics of 'Furanone quorum-sensing inhibitors with potential as novel therapeutics against Pseudomonas aeruginosa'. Together they form a unique fingerprint.

Cite this